Is Lancet Oncology Indexed in PubMed? Yes, and MEDLINE Is Active
The Lancet Oncology is indexed in PubMed and currently indexed for MEDLINE, which matters because top oncology papers need broad clinical and translational visibility.
Next step
Choose the next useful decision step first.
Use the guide or checklist that matches this page's intent before you ask for a manuscript-level diagnostic.
The Lancet Oncology at a glance
Key metrics to place the journal before deciding whether it fits your manuscript and career goals.
What makes this journal worth targeting
- IF 35.9 puts The Lancet Oncology in a visible tier — citations from papers here carry real weight.
- Scope specificity matters more than impact factor for most manuscript decisions.
- Acceptance rate of ~~8% means fit determines most outcomes.
When to look elsewhere
- When your paper sits at the edge of the journal's stated scope — borderline fit rarely improves after submission.
- If timeline matters: The Lancet Oncology takes ~14 days median. A faster-turnaround journal may suit a grant or job deadline better.
- If open access is required by your funder, verify the journal's OA agreements before submitting.
Quick answer: yes. The Lancet Oncology is indexed in PubMed and currently indexed for MEDLINE, with both lines beginning from volume 1, issue 1 in September 2000.
The important practical point is that discoverability is not the risk here. If a paper lands in The Lancet Oncology, it is fully visible in the standard oncology literature workflow. The harder question is whether the manuscript is consequential enough for the journal.
Direct answer
If you publish in The Lancet Oncology, your article is discoverable in PubMed and the journal sits inside the active MEDLINE system from launch.
The NLM record is unusually clean:
Record field | What the NLM Catalog shows for The Lancet Oncology | Why it matters |
|---|---|---|
Publication start | 2000 | The record starts with the journal's launch period. |
PubMed coverage | v1n1, Sept. 2000- | Papers are discoverable in PubMed from the first regular issue onward. |
MEDLINE coverage | v1n1, Sept. 2000- | The title has launch-to-present MEDLINE coverage. |
Current indexing status | Currently indexed for MEDLINE | This confirms active inclusion, not just historical presence. |
Current subset | Index Medicus | The title is in the core indexed-journal subset. |
NLM note | Preceded by a preview issue dated May 2000 | This helps explain why some readers see a prelaunch issue in the journal history. |
That is a strong, straightforward indexing record for a flagship oncology journal.
Why this matters for The Lancet Oncology specifically
Strong The Lancet Oncology papers are built to travel beyond one disease silo. They often need to reach:
- medical oncologists
- surgical and radiation oncology readers
- translational teams
- trialists and disease-group leaders
- guideline and review authors
Those readers usually search by disease, therapy class, biomarker, endpoint, or trial concept rather than by browsing a single issue. PubMed indexing matters because it is how the paper enters those real oncology search pathways.
PubMed and MEDLINE are answering different parts of the question
For this journal, the distinction is simple but still useful:
Signal | What it settles | What it does not settle |
|---|---|---|
PubMed | The paper will surface in standard oncology and biomedical search. | It does not tell you whether the paper is competitive for the journal. |
MEDLINE | The title is actively inside the curated NLM journal index. | It does not tell you whether the work is broad or consequential enough. |
Launch-to-present coverage | The discoverability record is stable from the journal's first regular issue. | It does not tell you whether a narrower oncology journal would be the smarter target. |
That is why indexing is the easy part of the decision. Once you know the title is fully indexed, the real decision moves back to audience, selectivity, and submission strategy.
How to verify the record yourself
The manual check is quick:
- open the NLM Catalog record
- confirm the PubMed line
- confirm the MEDLINE line
- check Current Indexing Status
- note the preview-issue detail
- run a direct journal search in PubMed
For The Lancet Oncology, this process is useful because it confirms that the record begins cleanly from the first regular issue and separates that fact from the journal's much harder editorial-bar question.
What we see in PubMed-Indexing Questions for The Lancet Oncology
For PubMed-indexing questions for The Lancet Oncology, three patterns show up repeatedly.
The prestige-over-evidence assumption. Some authors assume a Lancet journal does not need to be checked. Usually that assumption is directionally right, but the NLM record still gives the clean evidence and removes unnecessary guesswork.
The indexing-equals-fit shortcut. We also see teams solve the database question and then act as if the submission question is solved too. It is not. The title can be fully indexed and still be the wrong venue for a study that is too narrow, too early, or too incremental.
The broad-oncology confusion. Another common pattern is comparing The Lancet Oncology against more specialized journals as if search visibility is the main difference. It usually is not. The meaningful difference is audience breadth, consequence, and whether the manuscript can carry a field-wide oncology readership.
That is the real information gain here. The discoverability answer is yes. The selectivity and audience answer is separate.
Why this matters differently from a narrower oncology journal
The practical reason authors ask this about The Lancet Oncology is not usually fear that the journal is obscure. It is often uncertainty about what broad oncology discoverability is worth when compared with a narrower subspecialty venue.
Venue pattern | What indexing gives you | What it still does not decide |
|---|---|---|
broad flagship like The Lancet Oncology | search visibility across oncology subspecialties and translational readers | whether the paper is consequential enough for that audience |
narrower disease-specific journal | visibility inside one closer audience | whether the work deserves broader reach |
general medical journal | enormous discoverability if accepted | whether the oncology story is broad enough for a generalist readership |
That is the strategic use of this page. It confirms the database-status answer quickly, then pushes the real decision back to consequence, breadth, and venue fit.
It also clarifies that the audience question is not theoretical. A paper in The Lancet Oncology can get pulled into disease-specific searches, biomarker searches, methods reviews, and clinical-trial background work across subspecialties. That is why a strong launch-to-present PubMed and MEDLINE record matters even for a title whose reputation is already obvious.
It confirms the paper will travel widely if accepted, but it does not reduce the journal's editorial bar.
That is why indexing helps with confidence after acceptance, not with selectivity before it.
What the NLM record means in practice for authors
For authors, the The Lancet Oncology indexing record removes one whole category of concern. If a paper is accepted here, discoverability in the clinical and translational oncology literature is not the problem you need to worry about.
The cleaner use of this page is to clear that question fast, then move back to the harder strategic questions: is the manuscript broad enough, is the clinical or translational consequence high enough, and would the paper read like a top-tier oncology story to readers outside the immediate subfield?
That is also why we do not treat PubMed indexing as a proxy for journal quality. It is a discoverability fact. It does not replace editorial judgment about fit.
What indexing does and does not tell you
This page answers the discoverability question. It does not answer whether the manuscript is consequential enough or broad enough for The Lancet Oncology.
Indexing tells you:
- the paper will be visible in oncology search workflows
- the journal is actively indexed for MEDLINE
- the record is stable from launch
Indexing does not tell you:
- whether the paper has enough field-wide oncology consequence
- whether a narrower cancer journal would be a better target
- whether the current draft is ready for the journal's editorial bar
That is why the next useful pages are:
If the fit question is what you actually need answered, a Lancet Oncology submission readiness check gives you a manuscript-specific signal before you submit.
Submit If / Think Twice If
Use this indexing answer as enough reassurance if:
- your real concern is discoverability after publication
- you want confirmation that the title is actively inside PubMed and MEDLINE
- you are choosing among elite journals and need to rule out database-status uncertainty
Think twice if:
- you are using indexing as a proxy for editorial fit
- the manuscript may still be too narrow for a broad oncology audience
- what you really need is a selectivity or consequence judgment instead
Readiness check
Run the scan while the topic is in front of you.
See score, top issues, and journal-fit signals before you submit.
Practical verdict
Yes, The Lancet Oncology is indexed in PubMed and currently indexed for MEDLINE, with both lines beginning from volume 1, issue 1 in September 2000. If your question is whether a published paper will be visible in the main oncology search workflow, the answer is yes.
If your real question is whether the manuscript deserves a The Lancet Oncology audience rather than a narrower oncology venue, that remains a separate fit judgment. A Lancet Oncology submission readiness check is the best next step if you want that call before submission.
For a manuscript-specific signal before you submit, run a Lancet Oncology submission readiness check.
Or see example reports before you finalize.
Frequently asked questions
Yes. The Lancet Oncology is indexed in PubMed and currently indexed for MEDLINE according to the NLM Catalog.
Yes. The NLM Catalog shows PubMed and MEDLINE coverage from volume 1, issue 1 in September 2000.
Because Lancet Oncology papers are meant to reach oncologists, trialists, fellows, and review authors through search-driven oncology workflows.
Open the journal’s NLM Catalog record, check the MEDLINE and PubMed lines plus current indexing status, then confirm recent Lancet Oncology articles appear normally in PubMed.
Sources
- 1. The Lancet Oncology NLM Catalog record, NLM.
- 2. NLM Catalog help: current indexing status, NLM.
- 3. The Lancet Oncology homepage, Elsevier.
- 4. The Lancet Oncology information for authors, Elsevier.
Before you upload
Choose the next useful decision step first.
Move from this article into the next decision-support step. The scan works best once the journal and submission plan are clearer.
Use the scan once the manuscript and target journal are concrete enough to evaluate.
Anthropic Privacy Partner. Zero-retention manuscript processing.
Where to go next
Start here
Same journal, next question
- How to Submit to Lancet Oncology: Complete Guide
- How to Avoid Desk Rejection at Lancet Oncology
- Is Lancet Oncology a Good Journal? Impact Factor, Scope, and Fit Guide
- The Lancet Oncology Response to Reviewers: How to Answer the Statistical Reviewer and Win (2026)
- The Lancet Oncology 'Under Review': What Each Status Means
- Lancet Oncology Review Time: What to Expect From Submission to Decision
Supporting reads
Conversion step
Choose the next useful decision step first.
Use the scan once the manuscript and target journal are concrete enough to evaluate.